Market capitalization | $545.53m |
Enterprise Value | $407.88m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8,157.60 |
P/S ratio (TTM) P/S ratio | 10,910.60 |
P/B ratio (TTM) P/B ratio | 4.09 |
Revenue growth (TTM) Revenue growth | -81.36% |
Revenue (TTM) Revenue | $50.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Altimmune, Inc. forecast:
8 Analysts have issued a Altimmune, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.05 0.05 |
82%
82%
|
|
Gross Profit | -2.04 -2.04 |
-
|
|
EBITDA | -97 -97 |
12%
12%
|
EBIT (Operating Income) EBIT | -100 -100 |
17%
17%
|
Net Profit | -104 -104 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.
Head office | United States |
CEO | Vipin Garg |
Employees | 59 |
Founded | 1997 |
Website | www.altimmune.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.